RecruitingAsthma AcuteCOPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
Eligible age
18–85 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Sponsor: Connect Biopharm LLC
You may qualify if…
- ✓ Body weight of ≥40 kg and BMI ≤45 kg/m2 at SV1a.
- ✓ Physician-diagnosed asthma
- ✓ Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication.
- ✓ Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids.
- ✓ Participants in a stable condition, must have a historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb.
- ✓ Current acute asthma exacerbation requiring an urgent healthcare visit for treatment.
- ✓ Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation.
- ✓ Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation.
You may not qualify if…
- ✕ Regular use of immunosuppressive medication.
- ✕ Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension.
- ✕ Current or former smoker, with a smoking history of ≥5 pack-years if \<30 years old or ≥10 pack-years if ≥30 years old
- ✕ COPD and other clinically significant pulmonary disease other than asthma.
- ✕ Known or suspected history of immunosuppression.
- ✕ History of known immunodeficiency disorder or hepatitis B or C.
- ✕ History of alcohol abuse and/or drug abuse.
- ✕ Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix or other malignancies treated with apparent success with curative therapy.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07705737 · last updated 2026-10-27